"The granting of orphan drug designation to cinrebafusp alfa underscores the high unmet medical need that persists in the treatment of gastric cancer and reinforces our conviction in the importance of developing this program while setting a high bar for success to help patients with limited therapeutic options," said Stephen S. Yoder, President and Chief Executive Officer of Pieris. "We look forward to beginning the phase 2 trial of cinrebafusp alfa later this summer."
https://finance.yahoo.com/news/pieris-pharmaceuticals-receives-orphan-drug-120000808.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.